Stocks Health care SMNR
OTC · Health careSemnur Pharmaceuticals, Inc. (SMNR)
It posted a net loss of $167.7M. At June 30, 2026 it held $39K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Key facts about Semnur Pharmaceuticals, Inc.
- Net worth
- Semnur Pharmaceuticals, Inc. has a market value (market cap) of $71.4M at the latest share price, and shareholders' equity of -$29.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $5.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Semnur Pharmaceuticals, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Semnur Pharmaceuticals, Inc. does
Semnur Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker SMNR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$160.4M | -$0.78 | n/a |
| 2024 | n/a | -$4.7M | -$0.02 | n/a |
| 2023 | n/a | $632.5K | n/a | n/a |
| 2022 | n/a | -$419.4K | n/a | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Semnur Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 10, 2026
- July 7, 2026
- June 25, 2026
- May 13, 2026
- May 12, 2026Form POS AM filing POS AM
- April 30, 2026
- April 30, 2026Proxy statement DEF 14A
- April 23, 2026
- March 17, 2026
- February 27, 2026
Insider trades
What the people running Semnur Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about SMNR
What does Semnur Pharmaceuticals, Inc. do?
Semnur Pharmaceuticals, Inc. is a company in the Health care sector, listed on OTC as SMNR. Its shares trade on OTC under the ticker SMNR.
What is Semnur Pharmaceuticals, Inc.'s net worth?
Semnur Pharmaceuticals, Inc. has a market value (market cap) of $71.4M at the latest share price, and shareholders' equity of -$29.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Semnur Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $167.7M.
When did Semnur Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026.
When is Semnur Pharmaceuticals, Inc.'s next earnings report?
Semnur Pharmaceuticals, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SMNR with
Follow SMNR
Get an email when Semnur Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Semnur Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.